BioCentury
ARTICLE | Finance

Damage control

Why SV-led syndicate poured $33M into DNA damage repair play Artios

September 26, 2016 7:00 AM UTC

SV Life Sciences is going back for seconds in DNA damage repair, leading a $33.2 million series A round for Artios Pharma Ltd. This time, the firm is building the company for the long term and wants Artios to amass one of the broadest DDR pipelines in the industry.

Other investors in Artios' series A included AbbVie Ventures, Arix Bioscience plc, Cancer Research Technology (CRT) Pioneer Fund, Imperial Innovations Group plc (LSE:IVO) and Merck Ventures...